Drug Trial Radar · NCT04551300
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
Last checked: Nov 19, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Oct 13, 2020
Primary completion
Jun 30, 2022
Study completion Oct 15, 2022
Sponsor
- Lead sponsor
- Shanghai Alebund Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the tolerability, safety and efficacy of various dosages of VS-505 compared with Sevelamer Carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic kidney disease subjects receiving maintenance hemodialysis.
Conditions
- Hyperphosphatemia
Interventions
VS-505Drug
4 dosages of experimental drug
Sevelamer CarbonateDrug
Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum phosphorus change from baseline to end of treatmentTime frame: 6 weeks
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Zhongshan Hospital Xiamen University
Xiamen, Fujian, China
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Xingtai Medical College
Xingtai, Hebei, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
The Second People's Hospital of Changzhou
Changzhou, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Jilin Province People's Hospital
Changchun, Jilin, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Dalina Municipal Central Hospital
Dalian, Liaoning, China
The First Hospital of Dalian Medical University
Dalian, Liaoning, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong Universiity School of Medcine
Shanghai, Shanghai Municipality, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.